



## SUPPLEMENTARY INFORMATION 1

### TITLE

Transferable Exclusivity Extension Vouchers for Antimicrobials: Incentive Design, Implementation Challenges, and Policy Trade-Offs

### JOURNAL NAME

Applied Health Economics and Health Policy (AHEHP)

### AUTHOR INFORMATION

Mario García-Díaz. Andalusian School of Public Health, Granada, Spain. Doctoral Program in Economics and Business, University of Granada, Granada, Spain. Corresponding author: mario.99.mgd@gmail.com ORCID: 0009-0005-3443-4936

Jorge Mestre-Ferrándiz. Department of Economics, University Carlos III, Madrid, Spain. ORCID: 0000-0003-0529-1321

Jaime Espín. Andalusian School of Public Health, Granada, Spain. Instituto de Investigación Biosanitaria ibs., Granada, Spain. CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. ORCID: 0000-0001-7299-6554

### QUESTIONNAIRE ON TRANSFERABLE EXCLUSIVITY EXTENSION VOUCHER IN EUROPE

This questionnaire is part of the Horizon Europe project called **Health Innovation Next Generation Payment and Pricing Models (HI-PRIX)**. Specifically, we are working on task 2.3, which consists of identifying, and analysing, a series of financing mechanisms that could imply taking public investment in R&D into account during price negotiations.

The **Transferable Exclusivity Extension Voucher (TEE Voucher)** is an instrument that aims to incentivise the development of innovative antibiotics, a key element in the control and management of resistance. Our research interest in this voucher is because it is a *pull* incentive created by a public institution and because it aims to mitigate one of the major public health problems (antimicrobial resistance). Furthermore, and particularly relevant for HI-PRIX, pharmaceutical companies have to declare R&D costs and their source of funding (whether public or private) for the antibiotic as a requirement for obtaining this incentive.

Therefore, within this project, our objective is to carry out a case study in which we have to show how the TEE Voucher, which is part of the review of the EU Pharma Strategy, can work and how its characteristics (and particularly the request to submit data on R&D costs and sources of finance) can affect the attainment of public benefits when it is applied.

As part of our analysis, we are interviewing key stakeholders, and that is why we are contacting you. This document sets out a series of questions that respond to our research objectives. We expect the interview to last 60 minutes.

The information we receive will be used for the sole and exclusive purpose of our research within the HI-PRIX project. We, the researchers, declare that we have no conflict of interest. Also, should there be any sensitive answers, we undertake to respect this confidentiality, should the situation arise. Finally, this questionnaire will be completely anonymised in the context of our research, but should anyone wish to disclose their name, they are welcome to do so.





For further information, please contact:

|                                                                                                                                                                                      |                                                                                      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| <b>Mario Garcia-Diaz. Tecnico Proyecto HI-PRIX</b><br>Email: <a href="mailto:mario.garcia.easp@juntadeandalucia.es">mario.garcia.easp@juntadeandalucia.es</a><br>Phone: +34659409863 | <b>Jorge Mestre-Ferrandiz</b><br>Email: jormesfer13@gmail.com<br>Phone: +34699756638 |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|

## GENERAL QUESTIONS

1. What are the **objectives** to be achieved by the implementation of such a mechanism?
2. What would this mechanism be **facilitating**?
3. What are the **barriers** to implementation?
4. What are the **enablers** to implementation?
5. Are you aware of any **impact evaluation** of the mechanism?

## SPECIFIC QUESTIONS

1. Why is the **public intervention** through the TEE Voucher necessary?
2. What information will the pharmaceutical industry have to **declare** about the R&D process as a requirement for obtaining the TEE Voucher?
3. How will the requirement to submit information on **R&D costs and sources of funding** affect the pharmaceutical industry's decision on whether or not to continue with the development of the antibiotic? Can it be a **disincentive**?
4. As it currently stands, is the TEE Voucher a sufficient **incentive** to encourage innovation in the face of antimicrobial resistance?
5. How could the mechanism impact on the **final price** of the antibiotic?
6. How will the TEE Voucher be able to support the **sustainability and efficiency** of the public health system?

